Plotted Points Statistics |
1,7-DIMETHYLXANTHINE (P-XANTHINE) |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 79% | 16% | 77% | 23% |
Total | 11 | 79% | 16% | 77% | 23% |
Sample Statistics |
1,7-DIMETHYLXANTHINE (P-XANTHINE) |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 1 | 9% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Sample Statistics |
10-HYDROXY-AMITRIPTYLINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 0 | 0% | 0 out of 31 |
Plotted Points Statistics |
ABACAVIR |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 61% | 8% | 62% | 7% |
Total | 14 | 61% | 8% | 62% | 7% |
Sample Statistics |
ABACAVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
ACETAMINOPHEN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 10 | 101% | 70% | 80% | 9% |
Total | 10 | 101% | 70% | 80% | 9% |
Sample Statistics |
ACETAMINOPHEN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 10 | 91% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 1 | 9% | 1 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Sample Statistics |
ACYCLOVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 13 | 42% | 13 out of 31 |
Plotted Points Statistics |
ALBUTEROL (SALBUTAMOL) |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 78% | 19% | 74% | 22% |
Total | 11 | 78% | 19% | 74% | 22% |
Sample Statistics |
ALBUTEROL (SALBUTAMOL) |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 6 | 55% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
ALPRAZOLAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 6 | 73% | 7% | 73% | 8% |
Total | 6 | 73% | 7% | 73% | 8% |
Sample Statistics |
ALPRAZOLAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 6 | . | |
False Negatives | 0 | 0% | 0 out of 6 |
Not Spiked | 26 | . | |
False Positives | 0 | 0% | 0 out of 25 |
Plotted Points Statistics |
AMITRIPTYLINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 46% | 20% | 48% | 17% |
Total | 14 | 46% | 20% | 48% | 17% |
Sample Statistics |
AMITRIPTYLINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 14 | 93% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
AMPHETAMINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 6 | 78% | 12% | 81% | 9% |
Total | 6 | 78% | 12% | 81% | 9% |
Sample Statistics |
AMPHETAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 86% | Spiked |
Estimated Values | 3 | 43% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 7 | . | |
False Negatives | 1 | 14% | 1 out of 7 |
Not Spiked | 25 | . | |
False Positives | 0 | 0% | 0 out of 24 |
Plotted Points Statistics |
ANTIPYRINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 76% | 8% | 76% | 9% |
Total | 11 | 76% | 8% | 76% | 9% |
Sample Statistics |
ANTIPYRINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
ATENOLOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 9 | 75% | 11% | 73% | 13% |
Total | 9 | 75% | 11% | 73% | 13% |
Sample Statistics |
ATENOLOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 9 | 82% | Spiked |
Estimated Values | 1 | 9% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 2 | 18% | 2 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
ATRAZINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 71% | 6% | 73% | 9% |
Total | 11 | 71% | 6% | 73% | 9% |
Sample Statistics |
ATRAZINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Sample Statistics |
BENZTROPINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 0 | 0% | 0 out of 31 |
Plotted Points Statistics |
BETAMETHASONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 92% | 14% | 91% | 14% |
Total | 14 | 92% | 14% | 91% | 14% |
Sample Statistics |
BETAMETHASONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 6 | 40% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
BUPROPION |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 5 | 39% | 7% | 38% | 4% |
Total | 5 | 39% | 7% | 38% | 4% |
Sample Statistics |
BUPROPION |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 5 | 83% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 6 | . | |
False Negatives | 1 | 17% | 1 out of 6 |
Not Spiked | 26 | . | |
False Positives | 0 | 0% | 0 out of 25 |
Plotted Points Statistics |
CAFFEINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 76% | 17% | 67% | 26% |
Total | 11 | 76% | 17% | 67% | 26% |
Sample Statistics |
CAFFEINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 2 | 10% | 2 out of 20 |
Plotted Points Statistics |
CARBAMAZEPINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 70% | 11% | 68% | 14% |
Total | 11 | 70% | 11% | 68% | 14% |
Sample Statistics |
CARBAMAZEPINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 2 | 10% | 2 out of 20 |
Plotted Points Statistics |
CARISOPRODOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 10 | 79% | 17% | 77% | 19% |
Total | 10 | 79% | 17% | 77% | 19% |
Sample Statistics |
CARISOPRODOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 10 | 91% | Spiked |
Estimated Values | 1 | 9% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 1 | 9% | 1 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
CHLORPHENIRAMINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 10 | 48% | 22% | 47% | 18% |
Total | 10 | 48% | 22% | 47% | 18% |
Sample Statistics |
CHLORPHENIRAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 10 | 67% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 5 | 33% | 5 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
CIMETIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 9 | 38% | 23% | 40% | 12% |
Total | 9 | 38% | 23% | 40% | 12% |
Sample Statistics |
CIMETIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 9 | 82% | Spiked |
Estimated Values | 9 | 82% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 2 | 18% | 2 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
CITALOPRAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 46% | . | 46% | 0% |
>= Reporting Level | 12 | 48% | 15% | 52% | 16% |
Total | 13 | 48% | 15% | 52% | 9% |
Sample Statistics |
CITALOPRAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 87% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 2 | 13% | 2 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
CLONIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 6 | 85% | 13% | 85% | 11% |
Total | 6 | 85% | 13% | 85% | 11% |
Sample Statistics |
CLONIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 100% | Spiked |
Estimated Values | 1 | 17% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 6 | . | |
False Negatives | 0 | 0% | 0 out of 6 |
Not Spiked | 26 | . | |
False Positives | 0 | 0% | 0 out of 25 |
Plotted Points Statistics |
CODEINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 5 | 64% | 21% | 62% | 17% |
Total | 5 | 64% | 21% | 62% | 17% |
Sample Statistics |
CODEINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 5 | 71% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 7 | . | |
False Negatives | 2 | 29% | 2 out of 7 |
Not Spiked | 25 | . | |
False Positives | 0 | 0% | 0 out of 24 |
Plotted Points Statistics |
COTININE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 88% | 15% | 87% | 22% |
Total | 11 | 88% | 15% | 87% | 22% |
Sample Statistics |
COTININE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 2 | 10% | 2 out of 20 |
Plotted Points Statistics |
DEHYDRONIFEDIPINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 77% | 11% | 77% | 11% |
Total | 14 | 77% | 11% | 77% | 11% |
Sample Statistics |
DEHYDRONIFEDIPINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 3 | 20% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Sample Statistics |
DESMETHYLDILTIAZEM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 5 | 16% | 5 out of 31 |
Plotted Points Statistics |
DESVENLAFAXINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 62% | 18% | 64% | 17% |
Total | 14 | 62% | 18% | 64% | 17% |
Sample Statistics |
DESVENLAFAXINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
DEXTROMETHORPHAN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 55% | 14% | 54% | 13% |
Total | 14 | 55% | 14% | 54% | 13% |
Sample Statistics |
DEXTROMETHORPHAN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
DIAZEPAM (VALIUM) |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 6 | 61% | 19% | 65% | 12% |
Total | 6 | 61% | 19% | 65% | 12% |
Sample Statistics |
DIAZEPAM (VALIUM) |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 6 | . | |
False Negatives | 0 | 0% | 0 out of 6 |
Not Spiked | 26 | . | |
False Positives | 0 | 0% | 0 out of 25 |
Plotted Points Statistics |
DILTIAZEM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 6 | 37% | 12% | 37% | 13% |
Total | 6 | 37% | 12% | 37% | 13% |
Sample Statistics |
DILTIAZEM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 100% | Spiked |
Estimated Values | 1 | 17% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 6 | . | |
False Negatives | 0 | 0% | 0 out of 6 |
Not Spiked | 26 | . | |
False Positives | 0 | 0% | 0 out of 25 |
Plotted Points Statistics |
DIPHENHYDRAMINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 55% | . | 55% | 0% |
>= Reporting Level | 12 | 72% | 11% | 70% | 12% |
Total | 13 | 70% | 11% | 70% | 12% |
Sample Statistics |
DIPHENHYDRAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 87% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 2 | 13% | 2 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Sample Statistics |
DULOXETINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 0 | 0% | 0 out of 31 |
Plotted Points Statistics |
ERYTHROMYCIN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 10 | 23% | 14% | 23% | 16% |
Total | 10 | 23% | 14% | 23% | 16% |
Sample Statistics |
ERYTHROMYCIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 10 | 67% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 5 | 33% | 5 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
EZETIMIBE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 8 | 50% | 20% | 50% | 14% |
Total | 8 | 50% | 20% | 50% | 14% |
Sample Statistics |
EZETIMIBE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 8 | 73% | Spiked |
Estimated Values | 8 | 73% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 3 | 27% | 3 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
FADROZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 68% | . | 68% | 0% |
>= Reporting Level | 13 | 68% | 11% | 72% | 13% |
Total | 14 | 68% | 11% | 71% | 13% |
Sample Statistics |
FADROZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
FAMOTIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 49% | 27% | 49% | 24% |
Total | 11 | 49% | 27% | 49% | 24% |
Sample Statistics |
FAMOTIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 73% | Spiked |
Estimated Values | 11 | 73% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 4 | 27% | 4 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
FENOFIBRATE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 10 | 39% | 16% | 38% | 19% |
Total | 10 | 39% | 16% | 38% | 19% |
Sample Statistics |
FENOFIBRATE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 10 | 91% | Spiked |
Estimated Values | 2 | 18% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 1 | 9% | 1 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
FEXOFENADINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 10 | 57% | 10% | 53% | 7% |
Total | 10 | 57% | 10% | 53% | 7% |
Sample Statistics |
FEXOFENADINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 10 | 91% | Spiked |
Estimated Values | 2 | 18% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 1 | 9% | 1 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
FLUCONAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 81% | 12% | 80% | 13% |
Total | 14 | 81% | 12% | 80% | 13% |
Sample Statistics |
FLUCONAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
FLUOXETINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 10 | 63% | 14% | 64% | 16% |
Total | 10 | 63% | 14% | 64% | 16% |
Sample Statistics |
FLUOXETINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 10 | 91% | Spiked |
Estimated Values | 10 | 91% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 1 | 9% | 1 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
FLUTICASONE PROPIONATE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 12 | 51% | 17% | 51% | 16% |
Total | 12 | 51% | 17% | 51% | 16% |
Sample Statistics |
FLUTICASONE PROPIONATE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 12 | 80% | Spiked |
Estimated Values | 4 | 27% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 1 | 7% | Spiked |
Spiked | 15 | . | |
False Negatives | 2 | 13% | 2 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
FLUVOXAMINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 25% | . | 25% | 0% |
>= Reporting Level | 13 | 28% | 14% | 25% | 20% |
Total | 14 | 27% | 14% | 25% | 20% |
Sample Statistics |
FLUVOXAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 14 | 100% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
GLIPIZIDE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 170% | . | 170% | 0% |
>= Reporting Level | 12 | 111% | 52% | 98% | 73% |
Total | 13 | 116% | 52% | 113% | 72% |
Sample Statistics |
GLIPIZIDE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 87% | Spiked |
Estimated Values | 7 | 47% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 1 | 7% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
GLYBURIDE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 73% | 20% | 70% | 23% |
Total | 11 | 73% | 20% | 70% | 23% |
Sample Statistics |
GLYBURIDE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Sample Statistics |
HYDROCODONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 0 | 0% | 0 out of 31 |
Plotted Points Statistics |
HYDROCORTISONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 83% | 11% | 84% | 13% |
Total | 14 | 83% | 11% | 84% | 13% |
Sample Statistics |
HYDROCORTISONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 5 | 33% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
HYDROXYZINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 63% | 10% | 63% | 11% |
Total | 11 | 63% | 10% | 63% | 11% |
Sample Statistics |
HYDROXYZINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
IMINOSTILBENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 73% | 19% | 74% | 21% |
Total | 13 | 73% | 19% | 74% | 21% |
Sample Statistics |
IMINOSTILBENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 87% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 2 | 13% | 2 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
KETOCONAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 41% | 13% | 42% | 10% |
Total | 14 | 41% | 13% | 42% | 10% |
Sample Statistics |
KETOCONAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 4 | 27% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
LAMIVUDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 84% | . | 84% | 0% |
>= Reporting Level | 10 | 75% | 17% | 73% | 13% |
Total | 11 | 76% | 16% | 76% | 17% |
Sample Statistics |
LAMIVUDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 73% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 4 | 27% | 4 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
LIDOCAINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 76% | 14% | 77% | 18% |
Total | 11 | 76% | 14% | 77% | 18% |
Sample Statistics |
LIDOCAINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 1 | 9% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
LOPERAMIDE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 6 | 34% | 12% | 36% | 10% |
Total | 6 | 34% | 12% | 36% | 10% |
Sample Statistics |
LOPERAMIDE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 100% | Spiked |
Estimated Values | 6 | 100% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 6 | . | |
False Negatives | 0 | 0% | 0 out of 6 |
Not Spiked | 26 | . | |
False Positives | 0 | 0% | 0 out of 25 |
Plotted Points Statistics |
LORATADINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 46% | 12% | 47% | 14% |
Total | 13 | 46% | 12% | 47% | 14% |
Sample Statistics |
LORATADINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 87% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 2 | 13% | 2 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
LORAZEPAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 88% | 16% | 90% | 10% |
Total | 14 | 88% | 16% | 90% | 10% |
Sample Statistics |
LORAZEPAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 93% | Spiked |
Estimated Values | 3 | 20% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
MEPROBAMATE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 6 | 80% | 8% | 78% | 3% |
Total | 6 | 80% | 8% | 78% | 3% |
Sample Statistics |
MEPROBAMATE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 6 | . | |
False Negatives | 0 | 0% | 0 out of 6 |
Not Spiked | 26 | . | |
False Positives | 0 | 0% | 0 out of 25 |
Plotted Points Statistics |
METAXALONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 76% | 14% | 75% | 13% |
Total | 11 | 76% | 14% | 75% | 13% |
Sample Statistics |
METAXALONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 100% | Spiked |
Estimated Values | 11 | 100% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 0 | 0% | 0 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
METFORMIN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 10 | 61% | 20% | 51% | 25% |
Total | 10 | 61% | 20% | 51% | 25% |
Sample Statistics |
METFORMIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 10 | 91% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 1 | 9% | 1 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
METHADONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 57% | . | 57% | 0% |
>= Reporting Level | 5 | 62% | 9% | 65% | 4% |
Total | 6 | 61% | 9% | 63% | 7% |
Sample Statistics |
METHADONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 86% | Spiked |
Estimated Values | 1 | 14% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 7 | . | |
False Negatives | 1 | 14% | 1 out of 7 |
Not Spiked | 25 | . | |
False Positives | 0 | 0% | 0 out of 24 |
Plotted Points Statistics |
METHOCARBAMOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 8 | 79% | 22% | 71% | 30% |
Total | 8 | 79% | 22% | 71% | 30% |
Sample Statistics |
METHOCARBAMOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 8 | 73% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 12 | . | |
False Negatives | 3 | 27% | 3 out of 11 |
Not Spiked | 20 | . | |
False Positives | 0 | 0% | 0 out of 20 |
Plotted Points Statistics |
METHOTREXATE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 83% | 37% | 65% | 47% |
Total | 13 | 83% | 37% | 65% | 47% |
Sample Statistics |
METHOTREXATE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 87% | Spiked |
Estimated Values | 13 | 87% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 2 | 13% | 2 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
METHYL-1H-BENZOTRIAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 110% | . | 110% | 0% |
>= Reporting Level | 13 | 83% | 13% | 82% | 13% |
Total | 14 | 85% | 15% | 83% | 17% |
Sample Statistics |
METHYL-1H-BENZOTRIAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
METOPROLOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 35% | 5% | 34% | 5% |
Total | 13 | 35% | 5% | 34% | 5% |
Sample Statistics |
METOPROLOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 87% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 2 | 13% | 2 out of 15 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Plotted Points Statistics |
MORPHINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 68% | 20% | 67% | 12% |
Total | 14 | 68% | 20% | 67% | 12% |
Sample Statistics |
MORPHINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
NADALOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 82% | . | 82% | 0% |
>= Reporting Level | 13 | 75% | 11% | 74% | 7% |
Total | 14 | 76% | 11% | 76% | 8% |
Sample Statistics |
NADALOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
NEVIRAPINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 72% | 9% | 73% | 8% |
Total | 13 | 72% | 9% | 73% | 8% |
Sample Statistics |
NEVIRAPINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 93% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 1 | 7% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
NICOTINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 40% | . | 40% | 0% |
>= Reporting Level | 13 | 72% | 33% | 71% | 24% |
Total | 14 | 70% | 32% | 66% | 26% |
Sample Statistics |
NICOTINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 2 | 12% | 2 out of 17 |
Plotted Points Statistics |
NIZATIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 64% | 30% | 61% | 22% |
Total | 13 | 64% | 30% | 61% | 22% |
Sample Statistics |
NIZATIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 93% | Spiked |
Estimated Values | 13 | 93% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 1 | 7% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
NORDIAZEPAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 87% | 23% | 84% | 12% |
Total | 14 | 87% | 23% | 84% | 12% |
Sample Statistics |
NORDIAZEPAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
NORETHINDRONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 72% | 14% | 73% | 11% |
Total | 13 | 72% | 14% | 73% | 11% |
Sample Statistics |
NORETHINDRONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 93% | Spiked |
Estimated Values | 2 | 14% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
NORFLUOXETINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 73% | . | 73% | 0% |
>= Reporting Level | 13 | 85% | 32% | 80% | 19% |
Total | 14 | 85% | 31% | 79% | 20% |
Sample Statistics |
NORFLUOXETINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 14 | 100% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Sample Statistics |
NORSERTRALINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 1 | 3% | 1 out of 31 |
Plotted Points Statistics |
NORVERAPAMIL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 26% | . | 26% | 0% |
>= Reporting Level | 13 | 31% | 18% | 25% | 25% |
Total | 14 | 31% | 17% | 26% | 25% |
Sample Statistics |
NORVERAPAMIL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 14 | 100% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
OMEPRAZOLE + ESOMEPRAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 33% | . | 33% | 0% |
>= Reporting Level | 7 | 31% | 9% | 31% | 7% |
Total | 8 | 31% | 8% | 32% | 7% |
Sample Statistics |
OMEPRAZOLE + ESOMEPRAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 8 | 57% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 6 | 43% | 6 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
ORLISTAT |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 21% | 15% | 17% | 15% |
Total | 11 | 21% | 15% | 17% | 15% |
Sample Statistics |
ORLISTAT |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 92% | Spiked |
Estimated Values | 11 | 92% | Spiked |
Deleted Values | 4 | 13% | Spiked + Not Spiked |
Spiked, Censored | 1 | 8% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 12 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 16 |
Sample Statistics |
OSELTAMIVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 0 | 0% | 0 out of 31 |
Plotted Points Statistics |
OXAZEPAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 37% | 33% | 16% | 43% |
Total | 13 | 37% | 33% | 16% | 43% |
Sample Statistics |
OXAZEPAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 93% | Spiked |
Estimated Values | 5 | 36% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 1 | 7% | 1 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
OXYCODONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 7 | 67% | 10% | 69% | 8% |
Total | 7 | 67% | 10% | 69% | 8% |
Sample Statistics |
OXYCODONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 7 | 100% | Spiked |
Estimated Values | 1 | 14% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 7 | . | |
False Negatives | 0 | 0% | 0 out of 7 |
Not Spiked | 25 | . | |
False Positives | 1 | 4% | 1 out of 24 |
Plotted Points Statistics |
PAROXETINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 12 | 27% | 15% | 21% | 22% |
Total | 12 | 27% | 15% | 21% | 22% |
Sample Statistics |
PAROXETINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 12 | 86% | Spiked |
Estimated Values | 12 | 86% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 2 | 14% | 2 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PENCICLOVIR |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 110% | 44% | 98% | 22% |
Total | 14 | 110% | 44% | 98% | 22% |
Sample Statistics |
PENCICLOVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 2 | 14% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PENTOXIFYLLINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 77% | 34% | 75% | 26% |
Total | 14 | 77% | 34% | 75% | 26% |
Sample Statistics |
PENTOXIFYLLINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 4 | 29% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PHENAZOPYRIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 93% | . | 93% | 0% |
>= Reporting Level | 12 | 87% | 36% | 86% | 22% |
Total | 13 | 87% | 34% | 86% | 19% |
Sample Statistics |
PHENAZOPYRIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 93% | Spiked |
Estimated Values | 5 | 36% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 1 | 7% | 1 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Sample Statistics |
PHENDIMETRAZINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 0 | 0% | 0 out of 31 |
Plotted Points Statistics |
PHENYTOIN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 81% | 18% | 81% | 18% |
Total | 14 | 81% | 18% | 81% | 18% |
Sample Statistics |
PHENYTOIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 2 | 14% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PIPERONYL BUTOXIDE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 51% | 24% | 55% | 19% |
Total | 13 | 51% | 24% | 55% | 19% |
Sample Statistics |
PIPERONYL BUTOXIDE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 93% | Spiked |
Estimated Values | 5 | 36% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 1 | 7% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PREDNISOLONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 74% | . | 74% | 0% |
>= Reporting Level | 13 | 74% | 24% | 66% | 4% |
Total | 14 | 74% | 23% | 67% | 7% |
Sample Statistics |
PREDNISOLONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 2 | 14% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PREDNISONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 106% | . | 106% | 0% |
>= Reporting Level | 13 | 86% | 27% | 80% | 17% |
Total | 14 | 87% | 27% | 80% | 22% |
Sample Statistics |
PREDNISONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PROMETHAZINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 7 | 31% | 6% | 32% | 7% |
Total | 7 | 31% | 6% | 32% | 7% |
Sample Statistics |
PROMETHAZINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 7 | 50% | Spiked |
Estimated Values | 7 | 50% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 7 | 50% | 7 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PROPOXYPHENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 7 | 54% | 20% | 43% | 27% |
Total | 7 | 54% | 20% | 43% | 27% |
Sample Statistics |
PROPOXYPHENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 7 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 7 | . | |
False Negatives | 0 | 0% | 0 out of 7 |
Not Spiked | 25 | . | |
False Positives | 1 | 4% | 1 out of 24 |
Plotted Points Statistics |
PROPRANOLOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 69% | 12% | 68% | 15% |
Total | 14 | 69% | 12% | 68% | 15% |
Sample Statistics |
PROPRANOLOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
PSEUDOEPHEDRINE+EPHEDRINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 7 | 75% | 16% | 82% | 16% |
Total | 7 | 75% | 16% | 82% | 16% |
Sample Statistics |
PSEUDOEPHEDRINE+EPHEDRINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 7 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 7 | . | |
False Negatives | 0 | 0% | 0 out of 7 |
Not Spiked | 25 | . | |
False Positives | 1 | 4% | 1 out of 24 |
Plotted Points Statistics |
QUININE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 68% | 28% | 63% | 16% |
Total | 14 | 68% | 28% | 63% | 16% |
Sample Statistics |
QUININE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 6 | 43% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
RALOXIFENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 9 | 36% | 17% | 30% | 17% |
Total | 9 | 36% | 17% | 30% | 17% |
Sample Statistics |
RALOXIFENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 9 | 64% | Spiked |
Estimated Values | 9 | 64% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 5 | 36% | 5 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
RANITIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 20% | . | 20% | 0% |
>= Reporting Level | 13 | 64% | 37% | 63% | 44% |
Total | 14 | 61% | 37% | 57% | 45% |
Sample Statistics |
RANITIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 14 | 100% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
SERTRALINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 38% | . | 38% | 0% |
>= Reporting Level | 13 | 39% | 13% | 42% | 18% |
Total | 14 | 39% | 12% | 40% | 18% |
Sample Statistics |
SERTRALINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 14 | 100% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
SITAGLIPTIN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 4% | . | 4% | 0% |
>= Reporting Level | 12 | 33% | 26% | 35% | 35% |
Total | 13 | 31% | 27% | 34% | 28% |
Sample Statistics |
SITAGLIPTIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 93% | Spiked |
Estimated Values | 13 | 93% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
SULFADIMETHOXINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 110% | . | 110% | 0% |
>= Reporting Level | 13 | 85% | 18% | 82% | 18% |
Total | 14 | 87% | 18% | 83% | 22% |
Sample Statistics |
SULFADIMETHOXINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 3 | 21% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
SULFAMETHIZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 84% | 32% | 76% | 11% |
Total | 14 | 84% | 32% | 76% | 11% |
Sample Statistics |
SULFAMETHIZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 14 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
SULFAMETHOXAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 12 | 76% | 18% | 76% | 16% |
Total | 12 | 76% | 18% | 76% | 16% |
Sample Statistics |
SULFAMETHOXAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 12 | 86% | Spiked |
Estimated Values | 2 | 14% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 2 | 14% | 2 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
TAMOXIFEN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 2 | 10% | 5% | 10% | 6% |
Total | 2 | 10% | 5% | 10% | 6% |
Sample Statistics |
TAMOXIFEN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 2 | 22% | Spiked |
Estimated Values | 2 | 22% | Spiked |
Deleted Values | 12 | 38% | Spiked + Not Spiked |
Spiked, Censored | 2 | 22% | Spiked |
Spiked | 14 | . | |
False Negatives | 5 | 56% | 5 out of 9 |
Not Spiked | 18 | . | |
False Positives | 0 | 0% | 0 out of 11 |
Plotted Points Statistics |
TEMAZEPAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 7 | 68% | 11% | 70% | 16% |
Total | 7 | 68% | 11% | 70% | 16% |
Sample Statistics |
TEMAZEPAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 7 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 7 | . | |
False Negatives | 0 | 0% | 0 out of 7 |
Not Spiked | 25 | . | |
False Positives | 1 | 4% | 1 out of 24 |
Plotted Points Statistics |
THEOPHYLLINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 80% | . | 80% | 0% |
>= Reporting Level | 5 | 78% | 26% | 88% | 9% |
Total | 6 | 78% | 23% | 84% | 9% |
Sample Statistics |
THEOPHYLLINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 6 | 43% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 1 | 7% | Spiked |
Spiked | 15 | . | |
False Negatives | 7 | 50% | 7 out of 14 |
Not Spiked | 17 | . | |
False Positives | 1 | 6% | 1 out of 17 |
Plotted Points Statistics |
THIABENDAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 77% | . | 77% | 0% |
>= Reporting Level | 10 | 74% | 21% | 75% | 8% |
Total | 11 | 74% | 20% | 76% | 8% |
Sample Statistics |
THIABENDAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 79% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 2 | 14% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Sample Statistics |
TIOTROPIUM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 32 | . | |
False Positives | 0 | 0% | 0 out of 31 |
Plotted Points Statistics |
TRAMADOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 70% | 2% | 70% | 2% |
>= Reporting Level | 12 | 72% | 12% | 72% | 7% |
Total | 14 | 71% | 11% | 72% | 4% |
Sample Statistics |
TRAMADOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 1 | 7% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
TRIAMTERENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 87% | 18% | 78% | 21% |
Total | 11 | 87% | 18% | 78% | 21% |
Sample Statistics |
TRIAMTERENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 79% | Spiked |
Estimated Values | 5 | 36% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 2 | 14% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
TRIMETHOPRIM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 76% | . | 76% | 0% |
>= Reporting Level | 13 | 67% | 18% | 60% | 18% |
Total | 14 | 68% | 18% | 62% | 18% |
Sample Statistics |
TRIMETHOPRIM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
VALACYCLOVIR |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 2 | 6% | 4% | 6% | 4% |
Total | 2 | 6% | 4% | 6% | 4% |
Sample Statistics |
VALACYCLOVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 2 | 14% | Spiked |
Estimated Values | 2 | 14% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 12 | 86% | 12 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
VENLAFAXINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 13 | 59% | 10% | 60% | 8% |
Total | 13 | 59% | 10% | 60% | 8% |
Sample Statistics |
VENLAFAXINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 13 | 93% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 1 | 7% | 1 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |
Plotted Points Statistics |
VERAPAMIL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 14 | 22% | 13% | 21% | 20% |
Total | 14 | 22% | 13% | 21% | 20% |
Sample Statistics |
VERAPAMIL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 14 | 100% | Spiked |
Estimated Values | 0 | 0% | Spiked |
Deleted Values | 1 | 3% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 15 | . | |
False Negatives | 0 | 0% | 0 out of 14 |
Not Spiked | 17 | . | |
False Positives | 0 | 0% | 0 out of 17 |